<DOC>
	<DOCNO>NCT00134953</DOCNO>
	<brief_summary>This study design investigate efficacy safety rivastigmine compare placebo patient mild cognitive impairment ( MCI ) .</brief_summary>
	<brief_title>Efficacy Safety Rivastigmine Patients With Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Neurobehavioral Manifestations</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Males female one year postmenopausal without childbearing potential Between age 50 85 year old Mild cognitive impairment confirm Mini Mental State Examination ( MMSE ) score 23 27 Cooperative , able ingest oral medication , able complete aspect study capable , either alone aid responsible caregiver , accord investigator 's judgement A current diagnosis cerebrovascular disease , primary neurodegenerative disorder , cause neuropsychologic disturbance secondary dementia A current diagnosis epilepsy depression , diagnosis may interfere patient 's response study medication An advanced , severe unstable disease type may interfere efficacy evaluation Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Mild cognitive impairment</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Mild Cognitive Impairment ( MCI )</keyword>
</DOC>